IMU.AU stock price is influenced by several factors. Clinical Trial Outcomes: Positive data from Imugene's clinical trials, especially those showing significant efficacy and safety, tend to drive the stock price up. Conversely, negative or inconclusive results can lead to a price decrease. Regulatory Approvals: Progress towards regulatory approval for Imugene's products, such as positive interactions with regulatory bodies like the FDA and TGA, can positively impact the stock. Delays or rejections have the opposite effect. Partnerships & Licensing Deals: Collaborations with major pharmaceutical companies or successful licensing agreements for Imugene's technology can boost investor confidence and increase the stock price. Lack of partnerships could hinder growth. Market Sentiment: Overall investor sentiment towards the biotechnology sector and the Australian stock market can influence IMU.AU's price. Positive market trends often benefit the stock, while negative trends can depress it. Company News and Announcements: Major announcements regarding company strategy, financial performance, executive appointments, or research breakthroughs can significantly impact the stock price. Competition: The emergence of competing therapies or technologies from other companies in the immuno-oncology space can negatively affect Imugene's stock price.